Buprenorphine and a CRF1 Antagonist Block the Acquisition of Opiate Withdrawal-Induced Conditioned Place Aversion in Rats
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Conditioned place aversion in rats has face validity as a measure of the aversive stimulus effects of opiate withdrawal that reflects an important motivational component of opiate dependence. The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of opiate withdrawal. Male Sprague-Dawley rats were implanted with two subcutaneous morphine pellets and 5 days later began place conditioning training following subcutaneous administration of a low dose of naloxone. Animals were subjected to three pairings of a low dose of naloxone (15 microg/kg, s.c.) to one arm of a three-chambered place conditioning apparatus. Buprenorphine administered prior to each pairing dose-dependently blocked the place aversion produced by precipitated opiate withdrawal. A corticotropin-releasing factor-1 (CRF1) receptor antagonist (antalarmin) also reversed the place aversion produced by precipitated opiate withdrawal. Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats. No effect was observed with pretreatment of the dopamine partial agonist terguride or the selective serotonin reuptake inhibitor fluoxetine. Also, chronic pretreatment with acamprosate (a glutamate receptor modulator used to prevent relapse in alcohol depend…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Administration of a CRF receptor antagonist has been found to decrease opioid withdrawal-induced negative emotional states (54) and attenuated heroin self-administration in animals with extended access to the drug (55).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [54]
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Self-citationDrug abuse: hedonic homeostatic dysregulation
Koob, G. F., & Moal, M. L. (1997) · Science · doi:10.1126/science.278.5335.52 · Cited by 2,535 · cited 1×
“The purpose of the present study was to validate conditioned place aversion as sensitive to medications that will alleviate the aversive stimulus effects of opiate withdrawal in humans, and to extend this model to the exploration of the neuropharmacological basis of the motivational effects of…”
BackgroundSelf-citationKoob, G. F., Sanna, P. P., & Bloom, F. E. (1998) · Neuron · doi:10.1016/s0896-6273(00)80557-7 · Cited by 1,026
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Buprenorphine’s partial agonist properties limit its abuse liability (Jasinski et al, 1978), and it recently has been approved for use in the treatment opiate dependence (Johnson and McCagh, 2000; Tzschentke, 2002; Substance Abuse and Mental Health Services Administration, 2002).”
BackgroundZobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705 · cited 1×
“…that blocked shockinduced freezing did not compromise HPA axis responses to stress (Deak et al, 1999), and in clinical study the CRF1 antagonist R121919 produced anxiolytic-like effects in depressed patients in the absence of effects on basal or CRF-stimulated HPA axis measures (Zobel et al, 2000).”
BackgroundDynamics of Drug Dependence: Implications of a Conditioning Theory for Research and Treatment
Wikler, A. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750350005001 · Cited by 648 · cited 2×
“Opiate addiction long has been thought to involve multiple sources of reinforcement (Wikler, 1973).”
BackgroundCorticotropin-releasing factor, norepinephrine, and stress
Koob, G. F. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00164-x · Cited by 629 · cited 2×
“Because norepinephrine may release CRF in the basal forebrain, and CRF activates norepinephrine function in the pons, there is the possibility of a feedforward system involved in the aversive stimulus effects of opiate withdrawal as well as stress in general (Koob, 1999; Valentino et al, 1993).”
BackgroundSelf-citationPich, E., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G., & Weiss, F. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05439.1995 · Cited by 565 · cited 2×
“Studies using in vivo microdialysis have shown that rats withdrawn from chronic alcohol, withdrawn from chronic cocaine, and precipitously withdrawn from chronic cannabinoids show increases in the release of CRF from the central nucleus of the amygdala (Cummings et al, 1983; Merlo-Pich et al, 1995; Rodriguez de Fonsec…”
BackgroundSelf-citationA role for corticotropin releasing factor and urocortin in behavioral responses to stressors
Koob, G. F., & Heinrichs, S. C. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01991-5 · Cited by 531 · cited 1×
“These same central CRF systems are well documented to contribute to behavioral responses to stressors (Koob et al, 1994; Koob and Heinrichs, 1999).”
BackgroundSelf-citationAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528 · cited 1×
“Buprenorphine is an opioid partial agonist at the m opioid receptor and a k opioid antagonist (Cowan et al, 1977).”
Background
Research works printed but not linked: 1
- Valentino RJ, Foote SL, Page ME (1993). The locus coeruleus as a site for integrating corticotropin-eleasing factor and noradrenergic mediation of stress responses. In: Tache Y, Rivier C (eds). Corticotropin-Releasing Factor and Cytokines: Role in the Stress Response (series title: Annals of the New York Academy of Sciences, Vol. 697). New York Academy of Sciences: New York. pp 173–188.
Cited by
Items 101–139 of 139
Koob, G. F., & Moal, M. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012419239-3/50041-2 · Cited by 8
Self-citationBilel, S., Neto, J. A., Tirri, M., Corli, G., Bassi, M., Fantinati, A., Serpelloni, G., Malfacini, D., Trapella, C., Calò, G., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17333 · Cited by 8
“…of functional antagonism of corticotropin-releasing factor (CRF) neurotransmission, in particular CRF 1 receptors, in reducing stress and ameliorating negative affective-like states associated with opioid withdrawal and dependence (Heinrichs et al., 1995; Shaham et al., 1998; Stinus et al., 2005).”
García-Carmona, J. A., Laorden, E. M., Milanés, M. V., & Laorden, M. L. (2015) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.01.002 · Cited by 6
Stickney, J. D., & Morgan, M. M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05906-8 · Cited by 6
Baidoo, N., & Leri, F. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109018 · Cited by 6
Song, X., Li, W., Shi, Y., Zhang, J., & Li, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19671 · Cited by 6
“Conditioned place aversion (CPA) is a widely used model in exploring the biological mechanisms underlying aversive motivation induced by acute and chronic opiate addiction withdrawal [14, 15].”
BackgroundThe “homeostasis hormone” and its CRF1 receptor. From structure to function
Fahmy, H. T. Y., Spyridaki, K., Kuppast, B., & Liapakis, G. (2012) · HORMONES · doi:10.14310/horm.2002.1355 · Cited by 9
CRF1 receptor antagonists: treatment of stress-related disorders
Kehne, J. H., & Maynard, G. D. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.09.003 · Cited by 6
Iversen, L. L., Morris, K., & Nutt, D. J. (2007) · Elsevier eBooks · doi:10.1016/b978-012370624-9/50009-8 · Cited by 7
Schneider, P., Goldbaum, D., Agarwal, A., Taylor, A., Sundberg, P., Gardner, E. L., Ranaldi, R., You, Z., & Galaj, E. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173931 · Cited by 5
Draghmeh, K., & Fuehrlein, B. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26361 · Cited by 6
“They found that these antagonists effectively reduced anxiety-like behaviors and conditioned place aversion (CPA) in rats, indicating that CRF plays a crucial role in the negative affective states of opioid withdrawal [56].”
Intermittent Extended Access Rodent Models of Compulsive Eating
Zorrilla, E. P., Kreisler, A. D., & Bagsic, S. R. S. (2020) · Neuromethods · doi:10.1007/978-1-0716-0924-8_8 · Cited by 3
Self-citationNeurobiological theories of addiction
Koob, G. F., Arends, M. A., McCracken, M. L., & Moal, M. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816863-9.00003-0 · Cited by 3
Self-citationKoob, G. F., Arends, M. A., McCracken, M. L., & Moal, M. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-816988-9.00001-1 · Cited by 2
Self-citationKoob, G. F., Arends, M. A., McCracken, M. L., & Moal, M. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816863-9.00002-9 · Cited by 2
Self-citationAnimal Models of Addiction: A Review
Ghazvini, H., Tamijani, S. M. S., & Rafaiee, R. (2022) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.10.4.92 · Cited by 1
Thinking outside the brain: Testing predictors of drug addiction anticipated by dislocation theory
Sharpley, J. (2014) · Summit (Simon Fraser University) · Cited by 1
Chang, S. L. (2011) · eScholarship (California Digital Library) · Cited by 1
Lunerti, V., Shen, Q., Li, H., Benvenuti, F., Soverchia, L., Narendran, R., Weiss, F., Cannella, N., & Ciccocioppo, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.21.550008 · Cited by 1
“induced reinstatement of morphine (63) and heroin seeking (64) and reduces the expression of somatic and affective opioid withdrawal signs (65-68).”
BackgroundSubstance Abuse and Dependence
Martín‐García, E., Robledo, P., Cuesta, J., & Maldonado, R. J. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch08
Radke, A. K. (2011) · University of Minnesota Digital Conservancy (University of Minnesota)
Drug Addiction: Transition from Neuroadaptation to Pathophysiology
Koob, G. F., & Moal, M. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012419239-3/50047-3 · Cited by 1
Self-citationVocci, F. J. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn041
The effects of progestins on animal models of cocaine bingeing and relapse.
Anker, J. J. (2009) · University of Minnesota Digital Conservancy (University of Minnesota)
Neuronal Mechanisms Mediating Acute Food Deprivation-Induced Reinstatement of Heroin Seeking
Tobin, S. W. (2012) · Spectrum Research Repository (Concordia University)
Contarino, A. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.029
Magalas, Z., & Wagner, H. (2006) · RWTH Publications (RWTH Aachen)
Grieder, T. E. (2012) · TSpace (University of Toronto)
Porru, S. (2020) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14109.2020.773444 · Cited by 1
Famitafreshi, H., & Morteza, K. (2020) · Journal of Addiction Medicine and Therapeutic Science · doi:10.17352/2455-3484.000043
“In this type of relapse is the appearance of anxiety, the emotional component of withdrawal syndrome occurs as the result of autonomic overstimulation [52,53].”
BackgroundApproche épidémiologique et évaluative des comportements addictifs
de Chazeron, I. (2009) · HAL
Substance dependence and abuse
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.024
(2022) · Society for Neuroscience eBooks · doi:10.1523/hon.012005
Reward mechanisms underlying substance use disorder: A role for learning and memory
Fetterly, T. L., Vera, V. A., & Wood, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15754-7.00063-8
Xie, X., Essoh, A., Chen, R., Wang, X., & Wang, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.22.733757
Lüscher, C., Python, L., Liu, Y., Chaudun, F., & Pascoli, V. (2026) · Neuron · doi:10.1016/j.neuron.2026.06.011 · Cited by 1
Metadata
- Authors
- Stinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F.
- Affiliations
- Université de Bordeaux (FR)
- Scripps Research Institute (US)
- Corresponding author
- Stinus, Luis
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-12
- Volume
- 30
- Issue
- 1
- Pages
- 90-98
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1980693070
- Cited by
- 139
- References
- 73
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 10 · 2015: 6 · 2014: 8 · 2013: 6 · 2012: 6
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Université de Bordeaux
- National Institutes of Health
- National Institute on Drug Abuse (DA04043, R01DA004043)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- buprenorphine, corticotropin-releasing factor 1 receptor, antalarmin, opioid withdrawal, conditioned place aversion, morphine dependence, naloxone, place conditioning, acamprosate, terguride, fluoxetine, glutamate receptor modulation
- MeSH terms
- Acamprosate, CRF Receptor, Type 1, Analgesics, Opioid, Animals, Avoidance Learning, Buprenorphine, Conditioning, Operant, Dose-Response Relationship, Drug, Drug Implants, Fluoxetine, Lisuride, Male, Morphine, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Pyrimidines, Pyrroles, Substance Withdrawal Syndrome, Taurine, Rats, Sprague-Dawley, Receptors, Corticotropin-Releasing Hormone, Antidepressive Agents, Second-Generation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.